Novocure sought to develop a new way to treat solid tumor cancers.
In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.
He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.
Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that low-intensity, alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This innovative treatment, Tumor Treating Fields, or TTFields, is a completely different approach to cancer therapy.
Nobody understood what I was doing,” Professor Palti said on his early development of TTFields therapy.
global treatment centers
indications in our clinical pipeline
Novocure corporate timeline
Since our founding in 2000, we have reached many key milestones. Click through to see some of our proudest moments.
Phase 3 pivotal trial in non-small cell lung cancer begins
Palti’s initial research from his basement laboratory has evolved to become an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.
We launched Optune® – our TTFields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, we received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide. We actively market for that indication in the United States, Germany and Switzerland.
The science of TTFields has the potential to extend beyond GBM. We have five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. We presented our phase 2 pilot data in pancreatic and ovarian cancers at our research and development day on Dec. 12, 2016. In 2016, we began our phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, we started our phase 3 pivotal trial in NSCLC. Internationally, more than 20 institutions are studying the effects of TTFields in cancer treatment.
Our company began with a patient-forward approach that continues to drive our mission today. With more than 15 years of research and many significant milestones, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients.
leadership at Novocure
Our leaders have extensive experience across the oncology, biotechnology and medical device industries.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
publicationsWe have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.